First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial - Babiker, A.; Castro nee Green, H.; Compagnucci, A.; Fiscus, S.; Giaquinto, C.; Gibbs, D.; Harper, L.; Harrison, L.; Hughes, H. D.; McKinney, R.; Melvin, A.; Mofenson, L.; et al. (The Lancet Infectious Diseases, 2011)